Our initial phase 1 clinical trials delivering intracranial CAR T cells (BrainChild-01 delivering human epidermal growth factor receptor 2 (HER2)-specific CAR T cells (NCT03500991)11; BrainChild-02 delivering EGFR806-specific CAR T cells12 (NCT03638167)) excluded patients with DIPG. This evidence concerns the gene ERBB2 and diffuse intrinsic pontine glioma.